CIP
GILD icon

Capital Insight Partners’s Gilead Sciences GILD Stock Holding History

Capital Insight Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-3,433
Closed -$233K – 75
2017
Q1 		$233K Sell
3,433
-18,117
-84% -$1.27M 0.21% 68
2016
Q4 		$1.54M Sell
21,550
-12,609
-37% -$937K 1.53% 30
2016
Q3 		$2.7M Sell
34,159
-464
-1% -$37.7K 2.6% 11
2016
Q2 		$2.89M Buy
34,623
+6,947
+25% +$617K 2.74% 11
2016
Q1 		$2.54M Buy
27,676
+14,512
+110% +$1.31M 2.58% 16
2015
Q4 		$1.33M Buy
+13,164
New +$1.37M 1.35% 38

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Insight Partners's GILD Position: Q2 2017 in Review

Capital Insight Partners sold out of Gilead Sciences (GILD) in Q2 2017, closing a stake of 3,433 shares — an estimated $233K sold.

Capital Insight Partners first reported a position in GILD in Q4 2015 and held it in 6 quarters. The position peaked at $2.89M in Q2 2016. 1,519 funds tracked by Wall St. Rank hold GILD as of Q2 2017.

  • Capital Insight Partners reported no remaining Gilead Sciences position as of Q2 2017 after selling out during the quarter.
  • Capital Insight Partners sold 3,433 Gilead Sciences shares in Q2 2017, an estimated $233K.
  • Capital Insight Partners first reported a position in Gilead Sciences in Q4 2015 and held it in 6 quarters.
  • Capital Insight Partners's Gilead Sciences position peaked at $2.89M in Q2 2016.
  • 1,519 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2017.

Based on Capital Insight Partners's 13F filing for Q2 2017, filed 20 Jul 2017.